These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 11975807

  • 1. Metformin and carbohydrate-modified diet: a novel obesity treatment protocol: preliminary findings from a case series of nondiabetic women with midlife weight gain and hyperinsulinemia.
    Mogul HR, Peterson SJ, Weinstein BI, Zhang S, Southren AL.
    Heart Dis; 2001; 3(5):285-92. PubMed ID: 11975807
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Syndrome W: a new model of hyperinsulinemia, hypertension and midlife weight gain in healthy women with normal glucose tolerance.
    Mogul HR, Weinstein BI, Mogul DB, Peterson SJ, Zhang S, Frey M, Gambert SR, Southren AL.
    Heart Dis; 2002; 4(2):78-85. PubMed ID: 11975838
    [Abstract] [Full Text] [Related]

  • 4. Beneficial effects of metformin in normoglycemic morbidly obese adolescents.
    Kay JP, Alemzadeh R, Langley G, D'Angelo L, Smith P, Holshouser S.
    Metabolism; 2001 Dec; 50(12):1457-61. PubMed ID: 11735093
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30.
    Glueck CJ, Fontaine RN, Wang P, Subbiah MT, Weber K, Illig E, Streicher P, Sieve-Smith L, Tracy TM, Lang JE, McCullough P.
    Metabolism; 2001 Jul; 50(7):856-61. PubMed ID: 11436194
    [Abstract] [Full Text] [Related]

  • 7. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.
    Pasquali R, Gambineri A, Biscotti D, Vicennati V, Gagliardi L, Colitta D, Fiorini S, Cognigni GE, Filicori M, Morselli-Labate AM.
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2767-74. PubMed ID: 10946879
    [Abstract] [Full Text] [Related]

  • 8. Carbohydrate modified diet & insulin sensitizers reduce body weight & modulate metabolic syndrome measures in EMPOWIR (enhance the metabolic profile of women with insulin resistance): a randomized trial of normoglycemic women with midlife weight gain.
    Mogul HR, Freeman R, Nguyen K, Frey M, Klein LA, Jozak S, Tanenbaum K.
    PLoS One; 2014 Aug; 9(9):e108264. PubMed ID: 25259787
    [Abstract] [Full Text] [Related]

  • 9. Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome.
    Glueck CJ, Wang P, Fontaine R, Tracy T, Sieve-Smith L.
    Metabolism; 1999 Apr; 48(4):511-9. PubMed ID: 10206447
    [Abstract] [Full Text] [Related]

  • 10. METFORMIN-SUSTAINED WEIGHT LOSS AND REDUCED ANDROID FAT TISSUE AT 12 MONTHS IN EMPOWIR (ENHANCE THE METABOLIC PROFILE OF WOMEN WITH INSULIN RESISTANCE): A DOUBLE BLIND, PLACEBO-CONTROLLED, RANDOMIZED TRIAL OF NORMOGLYCEMIC WOMEN WITH MIDLIFE WEIGHT GAIN.
    Mogul H, Freeman R, Nguyen K.
    Endocr Pract; 2016 May; 22(5):575-86. PubMed ID: 26789348
    [Abstract] [Full Text] [Related]

  • 11. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.
    Lund SS, Tarnow L, Frandsen M, Smidt UM, Pedersen O, Parving HH, Vaag AA.
    Eur J Endocrinol; 2008 Jan; 158(1):35-46. PubMed ID: 18166815
    [Abstract] [Full Text] [Related]

  • 12. High-Dose, Diazoxide-Mediated Insulin Suppression Boosts Weight Loss Induced by Lifestyle Intervention.
    Loves S, van Groningen L, Filius M, Mekking M, Brandon T, Tack CJ, Hermus A, de Boer H.
    J Clin Endocrinol Metab; 2018 Nov 01; 103(11):4014-4022. PubMed ID: 30202851
    [Abstract] [Full Text] [Related]

  • 13. Predictive value of glucose-insulin ratio in PCOS and profile of women who will benefit from metformin therapy: obese, lean, hyper or normoinsulinemic?
    Onalan G, Goktolga U, Ceyhan T, Bagis T, Onalan R, Pabuçcu R.
    Eur J Obstet Gynecol Reprod Biol; 2005 Dec 01; 123(2):204-11. PubMed ID: 16316811
    [Abstract] [Full Text] [Related]

  • 14. Clinical and endocrinological effects of 6 months of metformin treatment in young hyperinsulinemic patients affected by polycystic ovary syndrome.
    Loverro G, Lorusso F, De Pergola G, Nicolardi V, Mei L, Selvaggi L.
    Gynecol Endocrinol; 2002 Jun 01; 16(3):217-24. PubMed ID: 12192894
    [Abstract] [Full Text] [Related]

  • 15. Rosiglitazone is more effective than metformin in improving fasting indexes of glucose metabolism in severely obese, non-diabetic patients.
    Brunani A, Caumo A, Graci S, Castagna G, Viberti G, Liuzzi A.
    Diabetes Obes Metab; 2008 Jun 01; 10(6):460-7. PubMed ID: 17394563
    [Abstract] [Full Text] [Related]

  • 16. Metformin versus sibutramine in the treatment of hyperinsulinemia in chronically anovulating women.
    Lazurova I, Dravecka I, Kraus V, Petrovicova J.
    Bratisl Lek Listy; 2004 Jun 01; 105(5-6):207-10. PubMed ID: 15535111
    [Abstract] [Full Text] [Related]

  • 17. Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome.
    Ortega-González C, Cardoza L, Coutiño B, Hidalgo R, Arteaga-Troncoso G, Parra A.
    J Endocrinol; 2005 Jan 01; 184(1):233-9. PubMed ID: 15642799
    [Abstract] [Full Text] [Related]

  • 18. Effects of antihyperglycaemic therapies on proinsulin and relation between proinsulin and cardiovascular risk factors in type 2 diabetes.
    Hermann LS, Ranstam J, Vaaler S, Melander A.
    Diabetes Obes Metab; 1999 Jul 01; 1(4):227-32. PubMed ID: 11228758
    [Abstract] [Full Text] [Related]

  • 19. An observational study of reduction of insulin resistance and prevention of development of type 2 diabetes mellitus in women with polycystic ovary syndrome treated with metformin and diet.
    Glueck CJ, Goldenberg N, Sieve L, Wang P.
    Metabolism; 2008 Jul 01; 57(7):954-60. PubMed ID: 18555837
    [Abstract] [Full Text] [Related]

  • 20. Metformin for overweight women at midlife: a double-blind, randomized, controlled trial.
    Worsley R, Jane F, Robinson PJ, Bell RJ, Davis SR.
    Climacteric; 2015 Apr 01; 18(2):270-7. PubMed ID: 25333776
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.